ABSTRACT
OBJECTIVE: Yttrium-90 radioembolization is an emerging therapy for unresectable hepatocellular carcinoma (HCC). Although therapeutic response based on size has been evaluated in numerous studies, necrosis has been used as a criterion of response in only a few studies. The purpose of our study was to describe the imaging features of HCC after 90Y treatment and to compare size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]) with necrosis criteria and combined criteria (RECIST and necrosis) for assessment of response. MATERIALS AND METHODS: CT images of 42 patients with 76 90Y-treated HCC lesions were analyzed. We used four response criteria: WHO size, RECIST size, necrosis, and combined criteria (RECIST and necrosis). Imaging features of treated lesions included both nodular and peripheral rim enhancement. Survival was assessed with the Kaplan-Meier method. RESULTS: The response rate was 23% according to RECIST criteria, 26% according to WHO criteria, 57% according to necrosis criteria, and 59% according to combined criteria. Response according to necrosis and combined criteria was detected earlier than response according to size criteria alone. Ten responding lesions initially increased in size. After therapy, enhancing peripheral nodules increased in size in 10 lesions, decreased in size in two lesions, and disappeared in two lesions. Twenty-one of 25 lesions with thin rim enhancement after 90Y administration responded to treatment. The median survival times were 660 and 236 days for Okuda stage I and Okuda stage II disease, respectively. CONCLUSION: Use of combined size and necrosis criteria may lead to more accurate assessment of response to 90Y therapy than use of size criteria alone. Imaging features after 90Y treatment, including size, necrosis, peripheral enhancing nodules, and thin rim enhancement, are described.
Subject(s)
Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/radiotherapy , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/radiotherapy , Radiographic Image Interpretation, Computer-Assisted/methods , Risk Assessment/methods , Tomography, X-Ray Computed/methods , Yttrium Radioisotopes/therapeutic use , Adult , Aged , Brachytherapy/methods , Carcinoma, Hepatocellular/mortality , Female , Humans , Illinois/epidemiology , Liver Neoplasms/mortality , Male , Microspheres , Middle Aged , Necrosis/diagnostic imaging , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Treatment OutcomeABSTRACT
OBJECTIVE: Yttrium-90 radioembolization is an emerging treatment for liver malignancies. The purpose of this study was to evaluate the imaging response of liver metastases to 90Y microspheres based on size and necrosis criteria using CT and comparing the results to PET and to describe imaging features related to 90Y therapy. MATERIALS AND METHODS: We reviewed the imaging studies of 42 patients with unresectable liver metastases treated with lobar radioembolization with 90Y. CT response was determined using traditional size criteria (World Health Organization [WHO] and Response Evaluation Criteria in Solid Tumors [RECIST]), necrosis criteria, and combined criteria (RECIST and necrosis). We compared the response on CT with the response on PET. Complications of treatment were assessed. RESULTS: The response rate was 19% (8/42) by WHO criteria, 24% (10/42) by RECIST, 45% (19/42) by necrosis criteria, and 50% (21/42) by combined criteria. Stabilization of lesion size occurred in 50% of patients. Necrosis and combined criteria identified responders earlier than RECIST and WHO criteria. Seven responders by combined criteria had an increase in lesion size on initial follow-up and would have been considered nonresponders. PET scans were obtained in 23 patients (33 treated lobes). PET detected significantly more responses to treatment (21/33, 63%) than CT using RECIST (2/33, 6%) or combined criteria (8/33, 24%) (p < 0.05, McNemar test). Complications of treatment included radiation cholecystitis (10 patients, 23%) and liver edema (18 patients, 42%). CONCLUSION: The use of necrosis and size criteria on CT and correlation with PET may improve the accuracy of assessment of response to 90Y treatment in patients with liver metastases and detect response earlier than standard size criteria.
Subject(s)
Liver Neoplasms/diagnosis , Liver Neoplasms/radiotherapy , Positron-Emission Tomography/methods , Risk Assessment/methods , Tomography, X-Ray Computed/methods , Yttrium Radioisotopes/therapeutic use , Adult , Aged , Aged, 80 and over , Brachytherapy/methods , Female , Humans , Liver Neoplasms/secondary , Male , Middle Aged , Necrosis/diagnostic imaging , Nuclear Proteins , RNA-Binding Proteins , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Treatment OutcomeABSTRACT
OBJECTIVE: The purpose of this study was to describe the CT diagnosis of chyluria after partial nephrectomy. CONCLUSION: Fat in the bladder can be identified on CT after partial nephrectomy. This finding is caused by chyluria secondary to lymphatic injury and should not be mistaken for other abnormalities. Our study population did not need treatment of chyluria.
Subject(s)
Chyle/diagnostic imaging , Lymph Nodes/diagnostic imaging , Lymph Nodes/injuries , Lymphatic Diseases/diagnostic imaging , Lymphatic Diseases/etiology , Nephrectomy/adverse effects , Tomography, X-Ray Computed/methods , Adult , Aged , Female , Humans , Male , Middle Aged , Reproducibility of Results , Retrospective Studies , Sensitivity and SpecificityABSTRACT
OBJECTIVE: CT is the most widely used imaging technique for the diagnosis of islet cell tumors, but MRI may be better for detecting small lesions and metastases because of its optimal contrast resolution and ability to easily perform dynamic imaging. The purpose of this pictorial essay is to highlight the MRI features of these tumors and underscore potential pitfalls. CONCLUSION: Although classically considered well-defined, arterially enhancing lesions that are bright on T2-weighted sequences, pancreatic islet cell tumors have quite a broad spectrum of appearances. MRI is well suited for detecting and characterizing pancreatic islet cell tumors as well as their local effects and metastases.
Subject(s)
Adenoma, Islet Cell/diagnosis , Magnetic Resonance Imaging , Pancreatic Neoplasms/diagnosis , Adult , Female , Humans , Male , Middle Aged , Pancreatic Neoplasms/pathologyABSTRACT
OBJECTIVE: CT is the established imaging technique for evaluation of pancreatic adenocarcinoma. MRI, however, can play a major role in this disease. The objective of this study is to illustrate the strengths of MRI for evaluating pancreatic adenocarcinoma. CONCLUSION: The superior soft-tissue contrast of MRI compared with CT is useful in the detection and characterization of non-contour-deforming pancreatic masses. MRI compared with CT may be more sensitive in the detection of distant disease, better for defining appropriate surgical candidates, and better for characterizing small liver metastases and peritoneal and omental metastases.
Subject(s)
Adenocarcinoma/diagnosis , Magnetic Resonance Imaging , Pancreatic Neoplasms/diagnosis , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/secondary , Adult , Carcinoma, Pancreatic Ductal/diagnosis , Carcinoma, Pancreatic Ductal/diagnostic imaging , Diagnosis, Differential , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/secondary , Lymphatic Metastasis , Male , Middle Aged , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/pathology , Pancreatitis/diagnosis , Tomography, X-Ray ComputedABSTRACT
MR imaging has made significant advances in recent years, with an increasingly important role in the detection, characterization, and staging of pancreatic diseases. MRI is appealing as a noninvasive imaging modality as it can evaluate the pancreas, the vasculature, and the pancreaticobiliary ducts in a single examination. Advantages of MRI include its excellent soft tissue contrast resolution and anatomic detail and absence of ionizing radiation. This article reviews the utility of MRI and its use not only as a problem-solving tool but its potential use as a primary examination (similar to CT) in a wide variety of pancreatic diseases.
